BioSpace News Archive

Innovation Pharmaceuticals, a clinical stage biopharmaceutical company, announced that it has achieved full patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 clinical trial of Brilacidin for the treatment of moderate-to-severe COVID-19 in hospitalized patients.

Microbix Biosystems Inc., a life sciences innovator and exporter, announces that it has secured a third manufacturing site in Mississauga, Ontario, by way of a long-term lease agreement for a property adjacent to its two current sites.

4D Molecular Therapeutics, a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapies, announced that management will participate in the Goldman Sachs 42nd Annual Global Healthcare Conference on Tuesday, June 8 at 2:30 p.m. PT.

NeuroPace, Inc., a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy, reported financial results for the quarter ended March 31, 2021.

High rate of complete responses in RP1 skin cancer cohorts underscore the potential for profound patient benefit and supports the ongoing registration directed development programs

Algernon Pharmaceuticals Inc. announces it has initiated a new clinical research program for pancreatic cancer and NP-120.

Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, announced today that its CEO, Dr James Garner , will be presenting virtually at the upcoming LD Micro Invitational XI.

Histogen Inc. announced an update on its pipeline focus following a strategic evaluation of its regenerative medicine platform technology development programs with the goal of focusing on high value orthopedic indications, creating pipeline synergies and maximizing resources in an effort to further drive long-term shareholder value.

Motus GI Holdings, Inc., (NASDAQ: MOTS) (“Motus GI” or the “Company”), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, announced today the publication of data from the REDUCE (“Reliable Endoscopic Diagnosis Utilizing Cleansing Enhancement”) study in an article titled

Krystal Biotech Inc., the leader in redosable gene therapies for rare diseases, announced participation in two upcoming virtual investor conferences.